<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-62209</identifier>
<setSpec>0213-4853</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Neuroprotection in Parkinson&#146;s disease: analysis though group of expert&#146;s methodology</dc:title>
<dc:description xml:lang="en">Introduction. Currently used antiparkinsonian drugs neitherstop nor slow-down the progressive nature of the disease. The finalphase of PD is characterized by the presence of symptomsand signs resistant to dopaminergic agents, such as depression,dementia, freezing and falls. Therefore, it is urgent to develop therapies able to positively modify this outcome. Despite neuroprotectionis a research priority in PD, no effective strategieshave been found so far.Method. A key informants study was conducted. A group ofexperts in PD fulfilled a questionnaire of 10 questions to explorethe most important topics related to neuroprotection. Afterwardsa consensus about the cur-rent situation of neuroprotection inPD was established and future directions of development weresuggested.Results. Most of the answers emphasized the need of newconcepts, the limitations of animal models and the difficulties inthe difficulties in demonstrating a neuroprotective effects in humansowing to a lack of biomarkers. Some of the experts believethat we are already exerting a disease modifying effect.Conclusions. The concept of neuroprotection should be widened.Animal models should be improved. A reliable biomarkerto start neuroprotective therapies long before the appearance ofmotor symptoms and to evaluate the neuroprotective effect ofany therapy should be urgently developed (AU)</dc:description>
<dc:creator>Menéndez Guisasola, L</dc:creator>
<dc:creator>Sesar, A</dc:creator>
<dc:creator>Vela, L</dc:creator>
<dc:creator>Salvador, C</dc:creator>
<dc:creator>Balaguer, E</dc:creator>
<dc:creator>Mir, P</dc:creator>
<dc:creator>Compta, Y</dc:creator>
<dc:creator>Yáñez, R</dc:creator>
<dc:creator>García Ruiz, P</dc:creator>
<dc:creator>Bergaretxe, A</dc:creator>
<dc:creator>Campos, V</dc:creator>
<dc:creator>Kulisevski, J</dc:creator>
<dc:creator>Catalán, M. J</dc:creator>
<dc:creator>Cubo, E</dc:creator>
<dc:creator>Leiva, C</dc:creator>
<dc:creator>Fernández, J. M</dc:creator>
<dc:creator>Luquin, R</dc:creator>
<dc:creator>Linazasoro, G</dc:creator>
<dc:creator>Martínez Castrillo, J. C</dc:creator>
<dc:creator>Burguera, J. A</dc:creator>
<dc:creator>Herrero, M. T</dc:creator>
<dc:creator>Mínguez, A</dc:creator>
<dc:creator>López del Val, J</dc:creator>
<dc:creator>Vivancos, F</dc:creator>
<dc:creator>López Lozano, J. J</dc:creator>
<dc:creator>Aguilar, M</dc:creator>
<dc:creator>Vaamonde, J</dc:creator>
<dc:creator>Lezcanoo, E</dc:creator>
<dc:creator>Grandas, F</dc:creator>
<dc:creator>Chacón, J</dc:creator>
<dc:creator>Valldeoriola, F</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción. La terapia convencional basada en fármacos dopaminérgicosno frena ni ralentiza de modo significativo el cursoprogresivo de la enfermedad de Parkinson (EP). La fase final de la EPse caracteriza por la presencia de síntomas y signos resistentes a laterapia dopaminérgica (depresión, demencia, disartria, caídas, etc.).Es urgente desarrollar terapias que eviten llegar a estas fases deteniendoo retardando la progresión de la enfermedad. Sin embargo,no se dispone de estrategias neuroprotectoras efectivas.Método. Se realizó un estudio de informadores clave en el queexpertos en EP que cumplimentaron un cuestionario de 10 preguntassobre la problemática más importante en el área de la neuroprotecciónen la EP. Tras ello se estableció un consenso sobre la situaciónactual y se sugirieron nuevas direcciones de investigación.Resultados. La mayoría de respuestas coincidieron en la necesidadde nuevos conceptos, en las limitaciones de los actuales modelosanimales o las dificultades de demostrar un efecto protector en humanospor la falta de biomarcadores. Algunos participantes opinanque ya se está ejerciendo un cierto efecto modificador del curso dela enfermedad.Conclusiones. El concepto de neuroprotección debe ser ampliado,los modelos animales deben mejorarse y urge encontrar un biomarcadorfiable para planificar la terapia en fases más precoces ypara determinar el efecto neuroprotector (AU)</dc:description>
<dc:source>Neurologia;24(2): 113-124, mar. 2009. tab</dc:source>
<dc:identifier>ibc-62209</dc:identifier>
<dc:title xml:lang="es">Neuroprotección en la enfermedad de Parkinson: análisis a través de la metodología de informadores clave</dc:title>
<dc:subject>^d37619</dc:subject>
<dc:subject>^d4255</dc:subject>
<dc:subject>^d30602</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d10489^s22057</dc:subject>
<dc:subject>^d10489^s22054</dc:subject>
<dc:subject>^d10489^s22032</dc:subject>
<dc:subject>^d23568^s22044</dc:subject>
<dc:subject>^d841</dc:subject>
<dc:subject>^d32116^s22073</dc:subject>
<dc:subject>^d982^s22073</dc:subject>
<dc:subject>^d28608</dc:subject>
<dc:subject>^d32285</dc:subject>
<dc:type>article</dc:type>
<dc:date>200903</dc:date>
</metadata>
</record>
</ibecs-document>
